[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-340999-105":59,"doc-detail-340999-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","discovery-of-novel-anaplastic-lymphoma-kinase-alk-and-histone-deacetylase-hdac-dual-inhibitors-exhibiting-antiproliferative-activity-against-non-small-cell-lung-cancer","Discovery of novel anaplastic lymphoma kinase (ALK) and histone deacetylase (HDAC) dual inhibitors exhibiting antiproliferative activity against non-small cell lung cancer","","A series of novel benzimidazole derivatives were designed and synthesized by leveraging reported oral ALK and HDAC inhibitors, pracinostat. In enzymatic assays, compound 3b containing a 2-acyliminobenzimidazole core and a hydroxamic acid side chain inhibited both ALK and HDAC6 (IC50 = 16 nM and 1.03 µM). Compound 3b also suppressed ALK mutants linked to crizotinib resistance, including L1196M (IC50 = 4.9 nM), and reduced proliferation across multiple cancer cell lines. In vivo, 3b inhibited tumor growth by 85% in a human A549 xenograft model with minimal impact on body weight.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/discovery-of-novel-anaplastic-lymphoma-kinase-alk-and-histone-deacetylase-hdac-dual-inhibitors-exhibiting-antiproliferative-activity-against-non-small-cell-lung-cancer/340999/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/discovery-of-novel-anaplastic-lymphoma-kinase-alk-and-histone-deacetylase-hdac-dual-inhibitors-exhibiting-antiproliferative-activity-against-non-small-cell-lung-cancer/340999.png","ImageObject",300,407,{"name":92,"@type":93},"Finn","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-31","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":29},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"How were the dual ALK/HDAC inhibitors designed in this study?","Question",{"text":112,"@type":113},"The compounds were designed and synthesized based on the structures of reported oral ALK inhibitor and HDAC inhibitor, pracinostat.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"What inhibitory activity did compound 3b show in enzymatic assays?",{"text":117,"@type":113},"Compound 3b inhibited both ALK and HDAC6 with IC50 values of 16 nM and 1.03 µM, respectively.",{"name":119,"@type":110,"acceptedAnswer":120},"How did compound 3b perform in an in vivo A549 xenograft model?",{"text":121,"@type":113},"At 20 mg/kg, 3b inhibited tumor growth by 85% and had negligible effects on mean body weight.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},340999,1790680461,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":29,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":36,"preview_page_count":19,"preview_urls":145},34359740700684,"https://ap-avatar.wpscdn.com/avatar/1f400023980c374ae676?_k=1777273430885731487","ReseaRch aRticle  \nDiscovery of novel anaplastic lymphoma kinase (ALK) and histone deacetylase (HDAC) dual inhibitors exhibiting antiproliferative activity against non-small cell lung cancer  \nKang-li Wanga, tsung-Yu Yeha, Pei-chen hsub, tzu-hsuan Wongb, Jia-Rong liua, Ji-Wang cherna, Miao-hsialinb and chao-Wu Yua  \naschool of Pharmacy, college of medicine, national taiwan university, taipei, taiwan; bdepartment and Graduate Institute of microbiology, college of medicine, national taiwan university, taipei, taiwan  \nABSTRACT  \na series of novel benzimidazole derivatives were designed and synthesised based on the structures of reported oral available alK inhibitor and hDac inhibitor, pracinostat. in enzymatic assays, compound 3b, containing a 2-acyliminobenzimidazole moiety and hydroxamic acid side chain, could inhibit both alK and hDac6 (ic50 = 16 nM and 1.03 µM, respectively). compound 3b also inhibited various alK mutants known to be involved in crizotinib resistance, including mutant l 1196M (ic50, 4.9 nM). Moreover, 3b inhibited the proliferation of several cancer cell lines, including alK-addicted h2228 [cells. to](cells. to) evaluate its potential for treating cancers in vivo, 3b was used in a human a549 xenograft model with BalB/c nude mice. at 20 mg/ kg, 3b inhibited tumour growth by 85% yet had a negligible effect on mean body weight. these results suggest a attracting route for the further research and optimisation of dual alK/hDac inhibitors.  \nGRAPHICAL ABSTRACT  \nARTICLE HISTORY  \nreceived 10 august 2023 revised 14 december 2023 accepted 11 January 2024  \nKEYWORDS  \nalK; hdac; antimour; mutantresistance  \nIntroduction  \nanaplastic lymphoma kinase (alK), also known as cD246, is a receptor tyrosine kinase (RtK) classified as a member of the insulin receptor superfamily and expressed by the ALK gene. involved in development of the central nervous system, alK is expressed at high levels in the human foetus yet its expression is significantly diminished in normal adults.1 aberrant overexpression of alK has been found in various cancers, including anaplastic large-cell lymphoma,2 non–small cell lung cancer (Nsclc),3 neuroblastoma,4 renal cell carcinoma,5,6 breast cancer,3 and thyroid cancer.7 the oncogenic mechanisms of ALK involve increasing gene-copy number, activating point mutations (mainly in neuroblastoma),8 and formation of fusion-alK proteins. Fusion-alK proteins are formed by chromosomal translocation or inversion and can activate alK  \nkinase abnormally. the best-known example is the nucleophosminalK fusion protein (NPM-alK), which is created by a 2;5-chromosomal translocation. NPM-alK is recognised as an important factor resulting in a subset of anaplastic large-cell lymphoma. studies also indicate that half of all inflammatory myofibroblastic tumours have an alK gene rearrangement, particularly in young patients.9 the echinoderm microtubule-associated protein-like 4–alK fusion protein (eMl4-alK) is another well-studied oncogenic fusion-alK protein that was first associated with Nsclcin 2007.10, 11 Non-smoking Nsclc patients in particular show an enrichment in eMl4-alK and limited mutation of the epidermal growth factor receptor (eGFR), which restricts the efficacy of traditional eGFR-targeted therapeutics such as gefitinib and erlotinib.12, 13 alK-targeted agents are a promising strategy for such patients. crizotinib, approved in 2011 by the U.s. Food and Drug  \nCONTACT miao-hsia lin  [miaohsialin1012@ntu.edu.tw](miaohsialin1012@ntu.edu.tw) department and Graduate Institute of microbiology, college of medicine, national taiwan university, taipei, taiwan; chao-Wu yu  [stifenyu@ntu.edu.tw](stifenyu@ntu.edu.tw) school of Pharmacy, college of medicine, national taiwan university, taipei, taiwan  \n supplemental data for this article can be accessed online at [https://doi.org/10.1080/14756366.2024.2318645](https://doi.org/10.1080/14756366.2024.2318645) .  \n© 2024 national taiwan university. Published by Informa uK","cbCaipmOme3v28o3","https://ap.wps.com/l/cbCaipmOme3v28o3","pdf",4336828,16,"English","# Abstract\n# Graphical Abstract\n# Article History\n# Keywords\n# Introduction","[{\"question\":\"How were the dual ALK/HDAC inhibitors designed in this study?\",\"answer\":\"The compounds were designed and synthesized based on the structures of reported oral ALK inhibitor and HDAC inhibitor, pracinostat.\"},{\"question\":\"What inhibitory activity did compound 3b show in enzymatic assays?\",\"answer\":\"Compound 3b inhibited both ALK and HDAC6 with IC50 values of 16 nM and 1.03 µM, respectively.\"},{\"question\":\"How did compound 3b perform in an in vivo A549 xenograft model?\",\"answer\":\"At 20 mg/kg, 3b inhibited tumor growth by 85% and had negligible effects on mean body weight.\"}]","Discovery of novel anaplastic lymphoma kinase (ALK) and histone deacetylase (HDAC) dual inhibitors exhibiting antiproliferative activity against non-small cell lung cancer | PDF",1790039877,[146,150,154,158],{"page_no":8,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/b656996a84bd16480f8444e24ac1fb8d.webp",983,1272,{"page_no":14,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/c4fded727bc6ac3c511beba4476e7f5b.webp",982,1270,{"page_no":81,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/898f13d618caacc476fc2b9182fa6788.webp",981,1269,{"page_no":19,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/a8964aa1f7e06b5fd75ae89bc40ff974.webp",980,1268]